Royalty Pharma (RPRX) Cash & Equivalents (2019 - 2026)

Royalty Pharma has disclosed Cash & Equivalents across 8 years of filings, most recently posting $586.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $586.4 million, down 46.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $586.4 million (down 46.09% YoY), and the FY2025 annual result was $618.7 million, down 33.4% from the prior year.
• Cash & Equivalents came in at $586.4 million for Q1 2026 at Royalty Pharma, down from $618.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2.2 billion in Q2 2023 to a low of $477.0 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $950.1 million (2024), against an average of $1.2 billion.
• Across the five-year window, Cash & Equivalents jumped 152.75% in 2022 and sank 72.12% in 2023, its largest moves.
• Royalty Pharma's Cash & Equivalents stood at $1.7 billion in 2022, then tumbled by 72.12% to $477.0 million in 2023, then soared by 94.76% to $929.0 million in 2024, then plunged by 33.4% to $618.7 million in 2025, then fell by 5.22% to $586.4 million in 2026.
• The last three Cash & Equivalents figures came in at $586.4 million (Q1 2026), $618.7 million (Q4 2025), and $938.9 million (Q3 2025), per Business Quant data.